TORNTPHARM.BO
Torrent Pharmaceuticals LimitedExplain this page
Arphra AIPlain-English read on Torrent Pharmaceuticals Limited’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
Valuation multiples
| In USD | FY 2026 |
|---|---|
| Headline | |
| Market cap | $1.43T |
| Enterprise value | $1.57T |
| Multiples | |
| P / E | — |
| P / B | — |
| EV / EBITDA | — |
| EV / Sales | 11.21 |
| EV / FCF | 80.14 |
| Yields | |
| Earnings yield | +1.51% |
| Free cash flow yield | +1.37% |
| Dividend yield | — |
Profitability
| In USD | FY 2026 |
|---|---|
| Margins | |
| Gross margin | +48.81% |
| Operating margin | +24.76% |
| EBITDA margin | +24.76% |
| EBIT margin | +24.76% |
| Pre-tax margin | +20.54% |
| Net margin | +15.47% |
| Cost structure | |
| Cost of revenue / sales | +51.19% |
| R&D intensity | 0.00% |
| SG&A intensity | +19.40% |
| Effective tax rate | +25.56% |
Returns on capital
| In USD | FY 2026 |
|---|---|
| Returns | |
| Return on equity (ROE) | +12.30% |
| Return on assets (ROA) | +4.88% |
| Return on capital (ROC) | +10.62% |
| Return on invested capital (ROIC) | +6.63% |
| Asset turnover | +31.55% |
| DuPont · ROE decomposition | |
| Net margin | +15.47% |
| Asset turnover (× revenue / assets) | +31.55% |
| Equity multiplier (× assets / equity) | +251.99% |
Activity & efficiency
| In USD | FY 2026 |
|---|---|
| Turnover | |
| Asset turnover | 0.32 |
| Fixed-asset turnover | 2.61 |
| Inventory turnover | 2.28 |
| Receivables turnover | 4.60 |
| Payables turnover | 3.03 |
| Days outstanding | |
| Days sales outstanding (DSO) | 79.27 |
| Days inventory outstanding (DIO) | 160.06 |
| Days payables outstanding (DPO) | 120.27 |
| Cash conversion cycle | 119.05 |
Cash flow quality
| In USD | FY 2026 |
|---|---|
| Operating CF / Net income | 1.22 |
| FCF / Net income | 0.90 |
| FCF margin | +13.98% |
| OCF margin | +18.83% |
| CapEx / Revenue | +4.84% |
| CapEx / D&A | — |
| Stock-based comp / Revenue | 0.00% |
Per-share & shareholder yield
| In USD | FY 2026 |
|---|---|
| EPS · diluted | 63.92 |
| EPS · basic | 63.92 |
| Book value / share | 519.66 |
| Tangible BV / share | -321.20 |
| Sales / share | 413.13 |
| Operating CF / share | 77.78 |
| Free cash flow / share | 57.77 |
| Dividends / share | 38.09 |
| Payout ratio | +59.59% |
| Retention ratio | +40.41% |
Growth
| In USD | FY 2026 | CAGR |
|---|---|---|
| Top-line | ||
| Revenue · YoY | — | — |
| Gross profit · YoY | — | — |
| Profit | ||
| Operating income · YoY | — | — |
| EBITDA · YoY | — | — |
| Net income · YoY | — | — |
| Operating | ||
| EBIT · YoY | — | — |
| R&D · YoY | — | — |
| Per-share | ||
| EPS · diluted · YoY | — | — |
| EPS · basic · YoY | — | — |
Credit & leverage
| In USD | FY 2026 |
|---|---|
| Leverage | |
| Total debt | $150.25B |
| Net debt | $138.6B |
| Net debt / EBITDA | 4.00 |
| Debt / equity | 0.85 |
| Debt / assets | +33.91% |
| Equity / assets | +39.68% |
| Coverage | |
| EBITDA / interest expense | 8.99 |
| Operating income / interest | 8.99 |
| Interest expense | $3.85B |
| Liquidity | |
| Current ratio | 1.13 |
| Quick ratio | 0.61 |
| Cash ratio | 0.14 |
| Working capital | $10.49B |
| Working capital / revenue | +7.50% |
Historical multiples · μ ± σ bands
3 fiscal-year-end observations from key_metrics. Mean is dashed; light-green band is ±1σ, light-red band ±2σ. The dot marks the most recent value; the cheap / fair / rich verdict uses z-score against the issuer's own history (yields inverted — a high yield is cheap).
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| P / E | — | — | — |
| P / B | — | — | — |
| EV / EBITDA | — | — | — |
| EV / Sales | 11.21x | 9.75x | 8.87x |
| Earnings yield | 1.5% | 1.8% | 1.8% |
| FCF yield | 1.4% | 1.8% | 3.1% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| ROE | 25.8% | 25.2% | 24.2% |
| ROA | 4.9% | 12.8% | 11.0% |
| ROIC | 6.6% | 17.2% | 15.1% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / equity | — | — | — |
| Net debt / EBITDA | 4.00 | 0.71 | 0.91 |
| Interest coverage | — | — | — |
| Current ratio | 1.13x | 1.19x | 1.03x |
| Quick ratio | — | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).